ArticleAsian Pacific journal of cancer prevention : APJCP2025
Predisposition of an Intronic Duplication in CHEK2 Gene in the Cases of Breast Cancer from Balochistan.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAfter BRCA 1&2, CHEK2 is the most frequently predisposing altered gene causing breast cancer in female. The prime objective of the current study was to analyze germline CHEK2 variants and their association with breast cancer in Balochistani population.
methodsBreast cancer is among the most prevalent cancers worldwide and most common diagnosed cancer in women. Mutations in many proto-oncogenes and tumor suppressor genes lead to the development of cancer. Along with the highly penetrance genes BRCA1 and BRCA2 increase the risk of breast cancer, mutations in other genes including CHEK2, a tumor suppressor gene have also been reported to be associated with breast cancer. In current study CHEK2 gene was analyzed for variation in breast cancer patients and controls of Balochistani population. Sequencing results of the DNA samples of the registered cases of breast cancer in CENAR were analyzed using Chromas software and bioinformatics tools including BLAT and RNAfold web server.
resultsAn intronic variant c.319+38-43dupA falling 38 nucleotide away at splice donor site of the CHEK2 gene exon 2, in 9% breast cancer cases, was identified which has also been previously reported in non-Hodgkin Lymphoma cases. All the cases with identified variant, were affected with invasive ductal carcinoma. Higher tumor grade (III) was reported in >50% of the patients and > 70% of patients diagnosed with advanced stage of cancer. The RNA prediction results revealed the variant falling in the intronic region may code for miRNA that could play an important role in cancer progression.
conclusionOur results suggest that the intronic variant identified in breast cancer cases as well as reported previously may act as a cancer marker and causing a splice site disruption or altering the posttranscriptional modification of mRNA encoded by CHEK2 gene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.